Ipsen delivers outstanding sales growth in the first nine months of 2026 and further upgrades its full-year guidance

Ipsen reported significant sales growth for the first nine months of 2026, attributed to strong operational performance. As a result, the company has upgraded its full-year financial guidance for 2026, underscoring its success in core therapeutic areas. Additional details on specific financial metrics and the revised outlook were included in the latest company update.